Document is current

Article History

Received: 29 August 2020

Revised: 11 December 2020

Accepted: 15 December 2020

First Online: 8 January 2021

Compliance with ethical standards

:

: HN has received honoraria from Takeda Pharmaceutical, Otsuka Pharmaceutical, Bristol-Myers Squibb, Celgene, Pfizer, Novartis, Janssen Pharmaceutical, Eisai, Chugai Pharmaceutical, and Nippon Shinyaku. SK has received honoraria from Novartis, and Bristol-Myers Squibb. S.Fujisawa has received honoraria from Novartis and Pfizer; research grants from Astellas, Chugai Pharmaceutical, and Pfizer. TM has received honoraria from Pfizer, MSD, Janssen Pharma, Sumitomo Dainippon Pharma, Novartis, Kyowa Kirin, Chugai Pharmaceutical, Shionogi & Co., Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai, and Astellas; research funds from Astellas, MSD, Novartis, LSI Medience, Medical & Biological Laboratories, and Asahi Kasei Corporation. S.Fujiwara has received honoraria from Astellas, Celgene, Chugai Pharmaceutical, Eisai, Kyowa Kirin, Nippon Shinyaku, Novartis, Ortho Clinical Diagnostics, Otsuka Pharmaceutical, and Pfizer. SO has received honoraria from Pfizer, Janssen Pharmaceutical, and Astellas; and research funds from Sumitomo Dainippon Pharma, Pfizer, Teijin Pharma, Novartis, Bristol-Myers Squibb, Mochida Pharmaceutical, JCR Pharmaceuticals, Toyama Chemical, Takeda Pharmaceutical, Daiichi Sankyo, Shionogi & Co., Sanofi, Kyowa Kirin, Ono Pharmaceutical, Otsuka Pharmaceutical, Eisai, Asahi Kasei Corporation, and Japan Blood Products Organization. KU has received honoraria from Alexion Pharmaceuticals, SymBio Pharmaceuticals, Daiichi Sankyo, Otsuka Pharmaceutical, Novartis, Bristol-Myers Squibb, Ono Pharmaceutical, Celgene, Takeda Pharmaceutical, Nippon Boehringer Ingelheim, Kyowa Kirin, Eisai, MSD, SymBio Pharmaceuticals, PharmaEssentia, and Yakult; research grants from Astellas, Alexion Pharmaceuticals, AbbVie GK, Gilead, SymBio Pharmaceuticals, Daiichi Sankyo, Dainippon Sumitomo Pharma, Chugai Pharmaceutical, Otsuka Pharmaceutical, Novartis, Bristol-Myers Squibb, Ono Pharmaceutical, Janssen Pharmaceutical, Celgene Corporation, Takeda Pharmaceutical, Nippon Boehringer Ingelheim, Mundipharma, Astellas-Amgen-Biopharma, Apellis Pharmaceuticals, Nippon Shinyaku, Kyowa Kirin, and Pfizer. ES has received honoraria from Bristol-Myers Squibb; research funds from Novartis, Pfizer, and Bristol-Myers Squibb; and subsidies from Kyowa Kirin, Chugai Pharmaceutical, and Ono Pharmaceutical. SY has received honoraria from Daiichi Sankyo; and research grants from Kyowa Kirin, Astellas, Eli Lilly, Pfizer, Ono Pharmaceutical, Chugai Pharma, Mochida Pharma, MSD Pharma, and Dai Nippon Sumitomo Pharma. YK has received honoraria from MSD, Astellas, Sumitomo Dainippon Pharma, Chugai Pharmaceutical, Pfizer, Novartis, Otsuka Pharmaceutical, Eisai, and Janssen Pharmaceutical Kyowa Kirin, Takeda Pharmaceutical, Ono Pharmaceutical, Shionogi & Co., Bristol-Myers Squibb, Celgene, Mochida, Alexion, Takara-bio; research grants from Celgene, Astellas, Chugai Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Eisai, and Shionogi & Co., Otsuka pharmaceutical, Nippon-Shinyaku, Taiho, Pfizer, MSD, Asahi-Kasei Corporation, Sanofi, Novartis, Taisho-Toyama, CSL Behring, and Tanabe-Mitsubishi. The other authors report no potential competing conflicts of interest.